Differential Inhibite Effect of Xanthohumol on HepG2 Cells and Primary Hepatocytes

• Published in: Dose-response 2022-10, Vol.20 (4), p.155932582211360-15593258221136053
• Main Authors: Zhang, Xiuli, Wang, Tao, Zhou, Haihong, Li, Yonghui, Guo, Hongyun, Su, Haixiang
• Format: Article
• Language: English
• Subjects: Apoptosis; Liver cancer; Original
• ISSN: 1559-3258; 1559-3258
• DOI: 10.1177/15593258221136053

Xanthohumol (XN) is the major prenylated chalcone of the female inflorescences (cone) of the hop plant (Humulus lupulus). It is also a constituent of beer, the major dietary source of prenylated flavonoids. It has shown strong antitumorigenic activity towards various types of cancer cells. In the present study, we show the impact on human hepatocarcinoma cell line HepG2 cell and potential adverse effects on rat primary hepatocytes. Cell growth/viability assay (MTT) demonstrated that HepG2 cells are highly sensitive to XN at a concentration range of 25-100 μM. The primary mode of tumor cell destruction was apoptosis as demonstrated by the binding of Annexin Ⅴ-FITC, we show that XN at a concentration of 25 μM induced apoptosis in HepG2. Further evidence that XN kills HepG2 by inducing apoptosis was provided by the impact of XN on the cleavage of PARP-1 and caspases-3. In contrast, XN concentrations up to 100 μM did not affect viability of primary rat hepatocytes in vitro, meanwhile, XN did not induce the apoptosis of primary rat hepatocytes in vitro. In summary, our data provide a rationale for clinical evaluation of XN for the treatment of liver cancer.